Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02482168 · ClinicalTrials.gov registry record · Phase 1
Study of the CD40 Agonistic Monoclonal Antibody APX005M
A Phase 1 study of Cancer and Melanoma, sponsored by Apexigen America.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
- 3
- Study locations
NCT02482168: Completed Phase 1 study of Cancer and Melanoma, sponsored by Apexigen America.
NCT02482168 is a Phase 1 study of Cancer and Melanoma that has completed, run by Apexigen America. The registered enrollment target is 43 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02482168, a Phase 1 study of Cancer and Melanoma, has completed, sponsored by Apexigen America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is a phase 1 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M in adults with solid tumors. Study is intended to establish the maximum tolerated dose and the overall safety and tolerability of APX005M in 3 different administration schedules.
Primary Outcome
The rate of DLTs will be assessed in approximately 56 subjects. DLTs will include Grade 4 neutropenia, anemia, thrombocytopenia, Grade 3or 4 nausea, cytokine release syndrome and other Grade 3 non-hematological toxicity
Conditions Studied
Interventions
- DRUG APX005M
Study Locations (3)
California
- City of Hope - Duarte
Ohio
- Case Western Reserve University - Cleveland
Pennsylvania
- Abramson Cancer Center of The University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2015-05 |
| Est. Completion | 2018-06-19 |
| Phase | Phase 1 |
What the finished NCT02482168 record still lists
NCT02482168 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 6 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which APX005M is the first listed.
NCT02482168 reports a single indexed study location in California, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02482168 about?
NCT02482168 is a clinical study titled "Study of the CD40 Agonistic Monoclonal Antibody APX005M". This study is a phase 1 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M in adults with solid tumors. Study is intended to establish the maximum tolerated dose and the overall safety and tolerability of APX005M in 3 different administration schedules.
What is the current status of trial NCT02482168?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2015-05. Estimated completion is 2018-06-19.
What conditions does trial NCT02482168 study?
This clinical trial studies the following conditions: Cancer, Melanoma, Head and Neck Cancer, Urothelial Carcinoma, NSCLC.
What interventions are being tested in trial NCT02482168?
The interventions under investigation include: APX005M (DRUG).
Who is sponsoring clinical trial NCT02482168?
This trial is sponsored by Apexigen America, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02482168 being conducted?
This trial has 3 study locations across California, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02482168's enrollment target sits among peer trials
43 455th of 615 higher than 160 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia